Literature DB >> 8047256

Basic mechanisms of motor fluctuations.

J I Sage1, M H Mark.   

Abstract

Patients with Parkinson's disease generally have a smooth clinical response from levodopa therapy for the first 3 to 5 years. Motor fluctuations later become noticeable and may ultimately give way to unpredictable responses to treatment. Mechanisms responsible for motor fluctuations are not fully understood, but can be separated into three groups: (1) central pharmacokinetics, or delivery of dopamine from the presynaptic to the postsynaptic receptor; (2) peripheral pharmacokinetics, or delivery of levodopa from an exogenous source to the brain; and (3) pharmacodynamics, or alterations in the interactions between dopamine and the striatal receptor. Changes in central pharmacokinetics caused by diminished presynaptic dopamine storage capacity probably account for early end-of-dose "wearing-off." As patients lose further storage capacity, peripheral levodopa pharmacokinetics may play an important role in the fluctuation response from erratic gastric emptying or variables that change gut-to-blood and blood-brain barrier transport. Finally, erratic motor responses (eg, the "on-off" phenomenon) in advanced Parkinson's disease may be caused in part by alterations at the striatal dopamine receptor.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8047256

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  9 in total

1.  Treatment of dysautonomia in extrapyramidal disorders.

Authors:  Tjalf Ziemssen; Heinz Reichmann
Journal:  Ther Adv Neurol Disord       Date:  2010-01       Impact factor: 6.570

2.  Pharmacokinetic-pharmacodynamic relationship of levodopa with and without tolcapone in patients with Parkinson's disease.

Authors:  H Baas; F Zehrden; R Selzer; R Kohnen; J Loetsch; S Harder
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 6.447

3.  Comparison of the functional potencies of ropinirole and other dopamine receptor agonists at human D2(long), D3 and D4.4 receptors expressed in Chinese hamster ovary cells.

Authors:  M C Coldwell; I Boyfield; T Brown; J J Hagan; D N Middlemiss
Journal:  Br J Pharmacol       Date:  1999-08       Impact factor: 8.739

Review 4.  Treatment of dysautonomia in extrapyramidal disorders.

Authors:  Tjalf Ziemssen; Gerd Fuchs; Wolfgang Greulich; Heinz Reichmann; Michael Schwarz; Birgit Herting
Journal:  J Neurol       Date:  2011-05       Impact factor: 4.849

5.  Psychometric Properties of Activity, Self-Efficacy, and Quality-of-Life Measures in Individuals with Parkinson Disease.

Authors:  Vanina Dal Bello-Haas; Laura Klassen; M Suzanne Sheppard; Amy Metcalfe
Journal:  Physiother Can       Date:  2011-01-20       Impact factor: 1.037

6.  Hand preshaping in Parkinson's disease: effects of visual feedback and medication state.

Authors:  Luis F Schettino; Sergei V Adamovich; Wayne Hening; Eugene Tunik; Jacob Sage; Howard Poizner
Journal:  Exp Brain Res       Date:  2005-07-22       Impact factor: 1.972

Review 7.  Using liquid levodopa in the treatment of Parkinson's disease. A practical guide.

Authors:  M C Kurth
Journal:  Drugs Aging       Date:  1997-05       Impact factor: 3.923

Review 8.  Concentration-effect relationship of levodopa in patients with Parkinson's disease.

Authors:  S Harder; H Baas; S Rietbrock
Journal:  Clin Pharmacokinet       Date:  1995-10       Impact factor: 6.447

9.  Early Motor Fluctuations in a Patient with Striatonigral Degeneration.

Authors:  Fumihito Yoshii; Yusuke Moriya; Tomohide Ohnuki; Wakoh Takahashi; Masafuchi Ryo
Journal:  Case Rep Neurol       Date:  2016-12-13
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.